Overview of Dr. Amengual
Dr. Jennifer Amengual is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from New York Medical College and has been in practice 13 years. She is one of 378 doctors at New York-Presbyterian Hospital and one of 116 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She has more than 40 publications and over 500 citings.
Office
622 W 168th St
New York, NY 10032
Education & Training
- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2007 - 2010
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
- New York Medical CollegeClass of 2004
Certifications & Licensure
- FL State Medical License 2021 - Present
- NY State Medical License 2007 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
- Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Start of enrollment: 2013 Sep 09
- ACY-1215 for Relapsed/Refractory Lymphoid Malignancies Start of enrollment: 2014 Apr 02
- Join now to see all
Publications & Presentations
PubMed
- 7 citationsHow I treat posttransplant lymphoproliferative disorder.Jennifer E Amengual, Barbara Pro
Blood. 2023-10-26 - 35 citationsAurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell LymphomaKelly Zullo, Yige Guo, Laurence Cooke, Xavier Jirau-Serrano, Michael Mangone
Clinical Cancer Research. 2015-04-15 - 8 citationsSuccessful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD.Daniel Oren, Ersilia M DeFilippis, Dor Lotan, Kevin J Clerkin, Justin Fried
JACC. Cardiooncology. 2022-12-01
Abstracts/Posters
- Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT ActivatorsJennifer E Amengual, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 StudiesJennifer E. Amengual, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
- Pipeline Moves: Moderna’s Pandemic Influenza Vaccine Trial CompletesAugust 19th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: